Horizon H2020 extends to 2027: Discover how are optimized research projects with this strategy
EU Commision has announced the continuity of the Horizon H2020 projects for the next 2021-2027. The new programme, Horizon Europe, is proposing 100 billion for research and innovation.
This new programme will be built based on the achievements and success of the previous research and innovation programme (Horizon 2020) and it will keep the EU at the forefront of global research and innovation.
EU funding allows teams across countries and from diverse scientific disciplines to work together and achieve fruitful discoveries, making Europe a world-class leader in research and innovation.
A European Innovation Council (EIC), to help the most innovative start-ups and companies scale up their ideas
New EU-wide research and innovation missions, focusing on societal challenges and industrial competitiveness
Maximising the innovation potential across the EU
A new generation of European Partnerships and increased collaboration with other EU programmes
EMA tools to foster development of new and innovative medicines
The European Medicines Agency (EMA) released a new infosheet that provides regulatory and scientific guidance to foster development of new and innovative medicines.
The following tools are available to take the medicine from the early phases in the laboratory to the patient:
There are some companies with wide experience in these regulatory tools recommended by EMA, which are working hand to hand with biopharmaceuticals and biotechs for the optimal development of the innovative products. Lets take a look in the services of one of them.
Are you looking for a Horizon 2020 regulatory partner?
Deadlines are fast-approaching. Hence a regulatory partner can be part of a research and development consortium and carry out regulatory affairs activities and guide the product development strategy. With the guidance of a Scientific and Regulatory Affairs consultancy, many goals can be achieved:
To be able to rely on the decades of services to industry experience
To receive independent expert opinions
To give added value to your projects by validating your development and regulatory strategy
To take advantage of their international team and extensive partner network
To be able to rely on established working teams, always with the same contact person
To be able to count on ad-hoc support when you need it
To achieve success with complex registration procedures
To optimise your workflows and minimise maintenance of registered products
The international Scientific and Regulatory Affairs consultancy
Asphalion is an International Scientific and Regulatory Affairs consultancy firm based in Barcelona, Madrid and Munich. Is already participating in 5 H2020 projects (iHivarna, Elastislet, Myocure, Hivacar, nTrack), and the success achieved makes them willing to continue joining this programme.
It offers comprehensive services for Drug Development and Regulatory Affairs to Pharma, Biotech and Medical Devices companies.
Since 2000, they have consistently grown and now have over 100 professional consultants with backgrounds in Life sciences (Pharmacy, Chemistry, Biology, Biochemistry, Biotechnology, Medicine and Veterinary Medicine).
Their consultants are experts in their field and are in direct contact with EU agencies (EMA and NCAs) for the development and implementation of new regulatory standards.
“Asphalion provides a global range of services, for global clients. “
Their services range from early development, throughout the registration, until marketing and post-commercialization phases of the products.
Through their network as regulatory consultants, Asphalion is in a position to support the worldwide scientific & regulatory activities of the companies. In fact, they make use of a dedicated US agent in the fields of Pharma/Biotech, Medical Devices and In Vitro Diagnostics.
Upcoming topics open for the 2018-2019 calls in the area of Health are: understanding causative mechanisms in co- and multimorbidities, combinatorial therapies for complex disorders and approaches to improve prevention and/or treatment of infectious diseases.
Do not miss the opportunity to be part of this challenging program that brings innovation to market.
Deadlines for the first stage are fast-approaching (October 2018), so if you are interested in participating you need to step on it!